8505C
1
Discover top-quality products tailored for scientific and medical research. Request a personalized quote today
to enhance your projects.
The 8505C cell line originates from a 78-year-old female patient with undifferentiated thyroid carcinomas that displayed a progression from well-differentiated to undifferentiated carcinoma components. These cells exhibit a brisk population doubling time of 36 hours, signifying rapid growth. Genetic analysis pinpointed a specific mutation with a C:G to G:C transversion at the initial base of the p53 codon 248 in 8505C, while PCR-loss of heterozygosity assays validated the deletion of the p53 gene. In culture, these cells adopt an epithelial-like, adherent growth pattern, forming monolayers. Consequently, they serve as a valuable model for investigating thyroid carcinoma and p53-related tumorigenesis.
Why choose 8505c from AcceGen?
The 8505C cell line from AcceGen is characterized by its high viability and exceptional quality. It is delivered in a sterile state, rigorously tested to be negative for contaminants including bacteria, yeast, mycoplasma, HIV, HBV, and HCV. Furthermore, its identity is confirmed through STR analysis, ensuring the reliability and authenticity of the cell line for various research applications.
| Product Code | 8505c |
| Species | Human |
| Cat.No | ABC-TC0020 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Epithelial |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Thyroid |
| Disease | Thyroid Cancer |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Thyroid Cancer Cell Lines |
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
FOR RESEARCH USE ONLY
The 8505C cell line plays a pivotal role in advancing our understanding of thyroid carcinomas. It is extensively employed in research to evaluate the impact of potential drugs on inhibiting or inducing apoptosis in thyroid cancer cells, shedding light on the underlying regulatory pathways. Furthermore, it serves as a valuable tool for investigating the influence of p53 gene mutations in malignant transformation, offering insights into the molecular mechanisms involved in thyroid cancer progression and potentially facilitating the development of novel therapeutic strategies.
